

You are invited to attend a presentation on:

VALTOCO® Reliable Delivery of Rescue Therapy for Seizure Clusters

Date:

Wednesday, March 24, 2021

Virtual Meeting with Dr. Peters

Time:

04:00 PM EDT

NOTE: In accordance with PhRMA Code, only licensed healthcare professionals, nonprescribing medical staff, or other healthcare professionals connected with the provision of healthcare in the field of epilepsy may attend Neurelis speaker programs. Spouses or guests may not attend company speaker programs. Further, any transfer of value received (such as food or drink) pursuant to this speaker program may be reportable under state and federal transparency laws.

Presented by:

Dr. Jurriaan Peters, MD, PhD
Division of Epilepsy and Clinical Neurophysiology
Boston Children's Hospital
Assistant Professor of Neurology
Harvard Medical School
Boston, MA

Hosted by:

Sandra Spinelli
sspinelli@neurelis.com
518-669-3243

Registration:

<https://NeurelisMETS.com/VAL-ONL-VIR-NOM-00339>

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

Please see Important Safety Information on the following page.

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate
- Limit dosages and durations to the minimum required
- Follow patients for signs and symptoms of respiratory depression and sedation

Contraindications: VALTOCO is contraindicated in patients with:

- Known hypersensitivity to diazepam
- Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication

should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to a healthcare provider.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome”, can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzylalcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read the full [Prescribing Information](#), including Boxed Warning, for additional important safety information.

© Neurelis, Inc. 2020. All rights reserved.

NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are registered trademarks of Neurelis, Inc.

US-PRC-20-00168 05/2020

For more information about VALTOCO, visit VALTOCOHCP.COM